The Food and Drug Administration (FDA) has decided not to pursue further enforcement action against Boston-based wearable technology company Whoop regarding its Blood Pressure insights feature, which provides users with estimations of their blood pressure. The agency's revised stance was communicated in a closeout letter dated June 17, following earlier concerns about the device’s classification under medical device regulations.

In July 2025, the FDA issued a warning letter to Whoop, asserting that its Blood Pressure insights feature required regulatory clearance because it was intended to measure or estimate a user’s blood pressure—information inherently linked to diagnosing hypo- and hypertension. Whoop’s leadership countered by stating that the feature was intended solely for wellness purposes, rather than as a diagnostic or treatment tool, with CEO Will Ahmed emphasizing the company’s opposition to "regulatory overreach" limiting consumer access to health data.

The agency’s recent decision comes after Whoop made adjustments to the Blood Pressure insights feature and following the FDA’s updated regulatory guidance on wellness-related devices issued earlier this year. The new guidance clarifies that the FDA will generally not regulate wearable features that provide biometric readings, such as blood pressure, when intended to promote wellness rather than diagnose or treat medical conditions. Under these guidelines, wellness products must avoid claims or messaging that characterize data outputs as diagnostic or pathological.

Whoop plans a software update that will modify the user interface of its blood pressure feature by removing distinct color-coded boundaries that suggested diagnostic categories. Instead, the data will be displayed along a continuous color gradient, reinforcing its status as a wellness tool rather than a medical device. A company spokesperson indicated these changes are designed to prevent users from interpreting the readings as clinical diagnoses.

The FDA’s limited enforcement in this case has been seen as significant but narrowly applied, leaving open broader questions about where wellness products end and medical device regulation begins. Regulatory experts note that the agency’s consideration includes not only official claims but also the user experience and data presentation.

The FDA’s revised guidance has prompted several major manufacturers, including Oura and Samsung, to introduce blood pressure estimation features in their wearables. However, some medical researchers and regulatory specialists remain concerned about the reliability of photoplethysmography (PPG) sensor technology, commonly used in these devices, for accurately estimating blood pressure. The FDA has cleared very few cuffless blood pressure devices using PPG, often requiring stringent calibration measures.

Critics highlight that while such wellness features may empower users with more health data, inaccurate or poorly validated readings risk misleading consumers, potentially resulting in undue anxiety or false reassurance. Clinician-researchers have called for greater transparency regarding the accuracy, clinical utility, and actionability of these blood pressure estimates.

Despite these concerns, Whoop maintains that its feature offers meaningful wellness insights. CEO Ahmed stated, “The science is clear that understanding changes in blood pressure has significant wellness benefits,” and asserted that consumer access to such information supports better personal health management.

As wearable technology and health monitoring features continue to evolve, the FDA’s balancing act between consumer access and ensuring product reliability remains a key regulatory challenge. The ongoing debate underscores the complexity of defining digital health tools across the spectrum from wellness to medical diagnosis.